HUMAN IGG1 LAMBDA MONOCLONAL ANTIBODY AGAINST ALFA-SYNUCLEIN clinical trials

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy

This study is testing a new medicine, TAK-341, for Multiple System Atrophy (MSA). Researchers want to see if it's safe, and if it can help improve symptoms of MSA over 52 weeks, compared to a dummy treatment.